Dorte Lisbet Nielsen
Professor emeritus.
Primary fields of research
- Resistance mechanisms in cancer cells
- Early clinical oncologic trials (phase I)
- Studies concerning prognostic and predictive tumour markers in breast and colorectal cancer
- Clinical trials and treatment of breast and colorectal cancer
- Cardiotoxicity of cytotoxic and targeted treatment
- Response evaluation in oncology
Current research
Ongoing research includes 1) oncologic phase I trials, 2) predictive biomarkers (inclusive mikroRNA profiles) for sensitivity of chemotherapy and targeted treatment (irinotecan and cetuximab) in colorectal cancer patients, 4) predictive biomarkers in breast cancer 4) phase II studies of irinotecan in breast cancer in collaboration with Danish Breast Cancer Group (DBCG), 5) phase II studies concerning intrahepatic chemotherapy and 6) investigation of trastuzumab, anthracycline and 5-fluorouracil cardiotoxicity.
ID: 10804194
Most downloads
-
221
downloads
The Patient–Healthcare Professional Relationship and Communication in the Oncology Outpatient Setting: A Systematic Review
Research output: Contribution to journal › Review › Research › peer-review
Published -
220
downloads
Implications of ABCG2 Expression on Irinotecan Treatment of Colorectal Cancer Patients: A Review
Research output: Contribution to journal › Review › Research › peer-review
Published -
205
downloads
Topoisomerase I copy number alterations as biomarker for irinotecan efficacy in metastatic colorectal cancer
Research output: Contribution to journal › Journal article › Research › peer-review
Published